150 related articles for article (PubMed ID: 23957509)
1. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
Denne JS; Stone AM; Bailey-Iacona R; Chen TT
J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
[TBL] [Abstract][Full Text] [Related]
2. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
3. Evaluating and adjusting for premature censoring of progression-free survival.
Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
[TBL] [Abstract][Full Text] [Related]
4. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
5. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
Pignatti F; Hemmings R; Jonsson B
Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
[No Abstract] [Full Text] [Related]
6. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.
Mannino FV; Amit O; Lahiri S
J Biopharm Stat; 2013; 23(5):971-85. PubMed ID: 23957510
[TBL] [Abstract][Full Text] [Related]
8. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
Amit O; Mannino F; Stone AM; Bushnell W; Denne J; Helterbrand J; Burger HU
Eur J Cancer; 2011 Aug; 47(12):1772-8. PubMed ID: 21429737
[TBL] [Abstract][Full Text] [Related]
9. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
10. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
Zhang JJ; Zhang L; Chen H; Murgo AJ; Dodd LE; Pazdur R; Sridhara R
Clin Cancer Res; 2013 May; 19(10):2637-45. PubMed ID: 23532893
[TBL] [Abstract][Full Text] [Related]
11. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
Sun X; Li X; Chen C; Song Y
J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
[TBL] [Abstract][Full Text] [Related]
12. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
13. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
14. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
Kovalchik S; Mietlowski W
Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
[TBL] [Abstract][Full Text] [Related]
15. Influence of censoring on conclusions of trials for women with metastatic breast cancer.
Templeton AJ; Ace O; Amir E; Vera-Badillo F; Ocana A; Pond GR; Tannock IF
Eur J Cancer; 2015 Apr; 51(6):721-4. PubMed ID: 25728257
[TBL] [Abstract][Full Text] [Related]
16. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
Markman M
Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
[No Abstract] [Full Text] [Related]
17. Analysis of progression-free survival in oncology trials: some common statistical issues.
Carroll KJ
Pharm Stat; 2007; 6(2):99-113. PubMed ID: 17243095
[TBL] [Abstract][Full Text] [Related]
18. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
[TBL] [Abstract][Full Text] [Related]
20. General and statistical hierarchy of appropriate biologic endpoints.
Sargent D
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
